Are GLP-1s safe for older adults (65+)?

What the data says about age itself: the labels report no overall differences in safety or effectiveness in 65+ subgroups; SELECT — median age 61, heavy 65+ representation — delivered its cardiovascular benefit across age strata. For an older adult with obesity plus hypertension, arthritis, sleep apnea, or heart disease, the upside case is, if anything, stronger: each kilogram lost pays off across more conditions. The one concern that genuinely scales with age — sarcopenia. Muscle peaks decades earlier and declines yearly; an unguarded 15% weight loss at 70 draws down reserves that protect against falls, fractures, and dependence, and that rebuild only slowly at that age. The implications: - The protein floor (1.2–1.6 g/kg goal weight) and resistance training move from “strongly advised” to the price of admission — some geriatric-minded clinicians want the lifting habit established before the first injection. - Slower loss is better loss here: gentler titration, satisfaction with a lower maintenance dose, and zero tolerance for the under-eating spiral — appetite suppression on an already-modest appetite can quietly produce dangerous intake levels. The practical-management items: - Polypharmacy: more medications means more interaction review — diuretics plus GLP-1 dehydration risk, insulin/sulfonylurea cuts, and timing-sensitive pills on a slowed stomach all warrant one thorough pharmacist pass. - Dehydration hits harder: blunted thirst on top of age-blunted thirst; fluid anchoring matters more, especially in heat or with diuretics. - High-risk flags deserving genuine provider review (not auto-decline): 65+ with multiple comorbidities, 75+, frailty, or significant kidney decline. A program that flags these for human review is functioning correctly. - Medicare coverage is its own maze — the indication-based doors are mapped here. Net: age modifies the how — pace, protein, monitoring — far more than the whether.